Comparison of Angioplasty/Drug Coated Balloon/Laser + Drug Coated Balloon for Femoropopliteal Artery In-stent Restenosis

Inclusion Criteria:

• Patient of age > 18 years

• Patient with previously peripheral implanted stent(s) located in or extending to thepopliteal artery

• Patient who received this stent between 3-36 months before inclusion

• Patient with one or more in-stent restenosis lesion(s) > 70% in the same arterialsegment in association with clinical symptoms of claudication or an critical limbischemia with Rutherford classification of 2, 3, 4 or 5

• Reference vessel diameter between 4 and 7 mm

• Patient affiliated to a social security regimen

• EC-approved consent form signed by the participant and the investigator (must besigned prior initiation of any study related intervention)

Exclusion Criteria:

• Life expectancy >18 months

• Patient already included in this study (recruitment of the contralateral leg is notallowed)

• Patient contraindicated for the use of antiplatelet therapy

• Pregnant or breast-feeding women

• Patient with a target limb infection being treated

• Patient with a procoagulant blood disease

• Patient with history of contrast agents allergies

• Patient with intolerance to paclitaxel

• Patient with severe renal impairment (GFR <30 ml / min / 1.73 m²) or patient with acreatinine clearance <15 ml / min

• External compression of previously implanted stent

• Patient participating in any clinical trial using another investigational drug orproduct which could interfere with the interpretation of the trial results.

• Patient under trusteeship or guardianship

Angiographic exclusion criteria :

• Inflow (above) severe lesion >70% or occlusion untreated satisfactorily (residuallesion> 50%) before the management of the target lesion

• Perforation, dissection or lesions on the arterial network access requiring anassumption prior to randomization

• Stent fracture grade 4 or 5 at the target lesion